Last updated: February 23, 2026
What is the drug associated with NDC 59417-0104?
NDC 59417-0104 corresponds to Apretude (cabotegravir extended-release injectable suspension), manufactured by ViiV Healthcare. It is an injectable medication for prevention of HIV-1 infection.
Market Size and Demand Drivers
HIV Prevention Market
Apretude targets HIV pre-exposure prophylaxis (PrEP), a rapidly growing segment in infectious disease therapeutics. The US CDC reports approximately 1.2 million individuals eligible for PrEP, with only about 25% currently on it.
Growth Factors
- Efficacy: Approved in 2021, Apretude offers a bi-monthly injection, improving adherence over daily oral PrEP.
- Guideline Adoption: US CDC and other health authorities recommend injectable PrEP in high-risk populations.
- Market Penetration: Competition includes Truvada and Descovy; however, Apretude's dosing schedule offers an adherence advantage.
Market Penetration Estimates
- Initial penetration in 2022: 10%
- Projected penetration in 2025: 25%
- Penetration in high-prevalence regions (e.g., Southern US): higher, approximately 30%
Estimated Revenue Potential
- Current number of users: 250,000 (approximate)
- Average annual revenue per user: $10,000 (assuming list prices and reimbursement)
- Total addressable market: $2.5 billion; with growth, potentially $5 billion by 2025
Competitive Landscape
| Product |
Type |
Market Share (2022) |
Pricing (per dose) |
Dosing Schedule |
Approval Year |
| Apretude |
Injectable |
nascent, <10% |
$3,500 (per two-dose cycle) |
2-month interval |
2021 |
| Truvada |
Oral PrEP |
60% in PrEP market |
$1,400/month |
Daily |
2004 |
| Descovy |
Oral PrEP |
30% in PrEP market |
$1,200/month |
Daily |
2019 |
Price Projections (2023–2026)
Current Pricing
- Wholesale acquisition cost (WAC): approximately $3,500 per two-dose cycle
- Average reimbursement rate: approximately 80%
Future Pricing Trends
- Price Stability (2023–2024): Prices are expected to remain stable due to existing patent protections and limited direct competition.
- Potential Price Reductions (2025–2026): Entry of biosimilars or generics, if approved and marketed, could lead to a 15–25% price drop.
Medicaid and Commercial Payer Negotiations
- Payers negotiate discounted prices, which may reduce net prices for providers by 30–50%
- Price adjustments will impact revenue projections, especially as utilization increases.
Regulatory and Pricing Policies Impact
- Pricing Approvals: No formal price regulation exists for HIV PrEP medications in the US; prices are driven by market competition and negotiation.
- State Pricing Negotiations: Some states employ bulk purchasing strategies that could reduce costs further.
Revenue and Profitability Projections
| Year |
Estimated Users |
Market Share |
Revenue (USD millions) |
Notes |
| 2023 |
75,000 |
10% |
262.5 |
Based on current prices and coverage |
| 2024 |
125,000 |
15% |
656.25 |
Increased adoption |
| 2025 |
187,500 |
25% |
1,640.62 |
Price stability and expanded coverage |
| 2026 |
250,000 |
30% |
2,625 |
Possible price reductions |
Note: These estimates assume no significant price reductions and full reimbursement.
Key Takeaways
- Apretude faces growth potential driven by higher patient adherence and clinical acceptance.
- Total market size for HIV PrEP medications could reach $5 billion in the US by 2025.
- Price stability at current levels expected until biosimilar/generic competition emerges, potentially by 2025–2026.
- Payer negotiations will significantly influence net revenue realizations.
- Competition from oral agents remains, but injectable PrEP’s adherence benefit supports market growth.
FAQs
Q1: How does Apretude’s pricing compare to oral PrEP medications?
A1: Apretude’s typical wholesale price per cycle (~$3,500) exceeds 2-3 times the annual cost of oral PrEP (~$14,400), but it offers less frequent dosing, which can improve adherence.
Q2: What factors could influence Apretude’s market share?
A2: Adoption depends on clinical guidelines, payer coverage policies, patient preference, and competitive pricing strategies.
Q3: What risks could affect revenue projections for Apretude?
A3: Entry of biosimilars or generics, regulatory price controls, shifts in treatment guidelines, or changes in reimbursement policies.
Q4: How significant is the role of payer negotiations in price setting?
A4: Payer negotiations can reduce net prices by up to 50%, substantially impacting profitability and revenue projections.
Q5: When might biosimilar competition affect prizing?
A5: Biosimilars or generics could enter the market around 2025–2026, depending on patent litigation and regulatory approvals.
References
- Centers for Disease Control and Prevention. (2022). HIV Surveillance Report.
- ViiV Healthcare. (2021). FDA Approval of Apretude.
- IQVIA. (2022). US Market for HIV PrEP Drugs.
- U.S. Food and Drug Administration. (2021). Drug Approvals.
- Drug Price Data. (2022). Average Wholesale Price Trends.
